ZEB1 throttles therapeutic target, protecting KRAS-mutant lung cancer

March 13, 2019

A cellular identity switch protects a cancer-promoting genetic pathway from targeted therapy, researchers at The University of Texas MD Anderson Cancer Center today reported in Science Translational Medicine.

Working in cell lines and mouse models of lung cancer, a team led by Don Gibbons, M.D., Ph.D., associate professor of Thoracic/Head and Neck Medical Oncology, demonstrated how the KRAS-driven lung cancer cells defeat treatment by switching from stable, stationary cells into a type of mobile, resistant cell associated with embryonic development. They also found a drug combination that reversed that cellular transition and restored vulnerability to targeted therapy.

About 30 percent of all cancers have an activating mutation of KRAS, which triggers tumor initiation and progression through a signaling pathway called MAPK. While KRAS itself has not been successfully attacked by drugs, targeted therapy has been developed for MEK, one of the downstream proteins triggered by KRAS in the cancer-promoting MAPK cascade.

"MEK inhibitors have been tried in multiple clinical settings, including lung cancer, and the results have not been good," Gibbons said. "They haven't consistently worked for patients with KRAS mutations and it was unclear why."

Gibbons and colleagues set out to identify resistance mechanisms, working through MD Anderson's Lung Cancer Moon Shot™, part of its Moon Shots Program™, a collaborative effort to accelerate the development of scientific discoveries into clinical advances that save patients' lives.

Triggering epithelial cell shift into dangerous mesenchymal status

A series of cell line experiments and in vivo screens showed that certain cells in tumors have mutant KRAS and activated MAPK signaling, making them potentially vulnerable to MEK inhibition. These epithelial cells - which line or cover the body's organs - are not mobile and perform a specific function.

A second group of experiments established that MAPK signaling is regulated by a protein called ZEB1, which suppressed the IL17RD protein to shut down the signaling pathway in the presence of a KRAS mutation. ZEB1 expression transitions epithelial cells to a different cell type - mesenchymal cells.

This type of mesenchymal cell is normally active during embryonic development, Gibbons explained. As embryonic stem cells produce all the cell types needed for the developing embryo, epithelial cells take on a mesenchymal form that allows, for example, a lung cell to move to join other lung cells. Once in place, the cells revert to epithelial form to stay put and form the organ.

"Mesenchymal cells have a very high migratory and invasive capability because of their normal function during embryogenesis," Gibbons said. "This program, called epithelial to mesenchymal transition (EMT), is known to become activated during the development and progression of tumors."

This firing up of an embryonic process in adult cells has long been associated with cancer progression and metastasis and is a focus of Gibbons' lab.

"You take a well-differentiated epithelial cell that has a normal function, whether it's a kidney cell or a lung cell or a breast cell and they have a function and it's well-defined. All of a sudden you turn on particular EMT gene sets and now those cells behave like a 5-year-old instead of an adult cell because they are no longer regulated in the same way. They run off and begin behaving in a way that is not typical. And that is the epitome of cancer," Gibbons said.

When mouse models with KRAS mutant lung cancer tumors of either epithelial or mesenchymal type were treated with MEK inhibitors, the mesenchymal cells were resistant from the start. Epithelial cells responded well initially, but over 80 percent of the tumors became resistant over time.

"Those tumors that became resistant had undergone a robust epithelial to mesenchymal transition," Gibbons said.

Reversing EMT, restoring MAPK

Previous research by other labs had shown that a type of drug called a histone deacetylase (HDAC) inhibitor can reverse EMT, allowing mesenchymal cells to revert to epithelial cells. In this study, treating cells with an HDAC inhibitor suppressed ZEB1, reversed EMT and restored MAPK activity, making tumors vulnerable to MEK inhibitors.

Combination therapy with an HDAC inhibitor and a MEK inhibitor steeply shrank tumors in mice.

An analysis of several large datasets of human tumors validated a negative correlation between ZEB1 and a measure of MAPK pathway activity.

The team is conducting work on combination therapies to attack both epithelial and mesenchymal cells.

"Mesenchymal cells are not sensitive to MEK inhibitors even though they have mutant KRAS," Gibbons said. "If it's not signaling through MAPK what is the mutant KRAS signaling through, what is it dependent on for its survival?"

Research also focuses on combining a MEK inhibitor with immune checkpoint inhibitors that unleash an immune attack on tumors. Immunotherapy already has had a significant impact on lung cancer and could change the dynamics of cell resistance to MEK treatment.
-end-
A clinical trial will open soon combining the two approaches, the second such trial by MD Anderson lung cancer researchers.

Co-authors with Gibbons are first author David Peng, Samrat Kundu, Ph.D., Jared Fradette, and Lauren Byers, M.D., of Thoracic/Head and Neck Medical Oncology; Lixia Diao, Ph.D., Pan Tong, Ph.D., and Jing Wang, Ph.D., of Bioinformatics and Computational Biology; Jaime Rodriguez Canales, M.D., Pamela Villalobos, M.D., Barbara Mino and Ignacio Wistuba, M.D., of Translational Molecular Pathology; Rosalba Minelli, Ph.D., of Genomic Medicine; Michael Peoples, Christopher Bristow, Ph.D., Timothy Heffernan, Ph.D., and Alessandro Carugo, Ph.D., of the Institute for Applied Cancer Science at MD Anderson and Yanan Yang, Ph.D., of Mayo Clinic, Rochester, MN.

Peng is a graduate student in the MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences.

Researchers' disclosures of competing interests are listed in the paper.

University of Texas M. D. Anderson Cancer Center

Related Lung Cancer Articles from Brightsurf:

State-level lung cancer screening rates not aligned with lung cancer burden in the US
A new study reports that state-level lung cancer screening rates were not aligned with lung cancer burden.

The lung microbiome may affect lung cancer pathogenesis and prognosis
Enrichment of the lungs with oral commensal microbes was associated with advanced stage disease, worse prognosis, and tumor progression in patients with lung cancer, according to results from a study published in Cancer Discovery, a journal of the American Association for Cancer Research.

New analysis finds lung cancer screening reduces rates of lung cancer-specific death
Low-dose CT screening methods may prevent one death per 250 at-risk adults screened, according to a meta-analysis of eight randomized controlled clinical trials of lung cancer screening.

'Social smokers' face disproportionate risk of death from lung disease and lung cancer
'Social smokers' are more than twice as likely to die of lung disease and more than eight times as likely to die of lung cancer than non-smokers, according to research presented at the European Respiratory Society International Congress.

Lung cancer therapy may improve outcomes of metastatic brain cancer
A medication commonly used to treat non-small cell lung cancer that has spread, or metastasized, may have benefits for patients with metastatic brain cancers, suggests a new review and analysis led by researchers at St.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Lung transplant patients face elevated lung cancer risk
In an American Journal of Transplantation study, lung cancer risk was increased after lung transplantation, especially in the native (non-transplanted) lung of single lung transplant recipients.

Proposed cancer treatment may boost lung cancer stem cells, study warns
Epigenetic therapies -- targeting enzymes that alter what genes are turned on or off in a cell -- are of growing interest in the cancer field as a way of making a cancer less aggressive or less malignant.

Are you at risk for lung cancer?
This question isn't only for people who've smoked a lot.

Read More: Lung Cancer News and Lung Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.